Clinical Trial Update: 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs [Phase 2]

View source ↗

Summary

This document reports a Phase 2 clinical trial evaluating trametinib for Ras/MAPK pathway vascular anomalies, sponsored by Children’s Hospital of Philadelphia, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vascular Anomalies
• Vascular Malformations

Drugs mentioned

• MEKINIST (trametinib)

Snippet

Sponsor: Children's Hospital of Philadelphia | Conditions: Ras/MAPK Pathway Vascular Anomalies, Vascular Anomalies | Phase 2 | Status: ACTIVE_NOT_RECRUITING